Decitabine and sickle cell disease: Molecular therapy for a molecular disease

Pediatric Hematology and Oncology

Volumn 24, Issue 7, 2007, Pages 465-468

  Saunthararajah, Yogen ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BETA GLOBULIN; HISTONE DEACETYLASE INHIBITOR; HYDROXYUREA;

CLINICAL TRIAL; DNA METHYLATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; EPIGENETICS; GENE SILENCING; GENE THERAPY; GENOTOXICITY; HEMOGLOBINOPATHY; HUMAN; LOW DRUG DOSE; MALE FERTILITY; MOLECULAR THERAPY; MORBIDITY; MORTALITY; NEUTROPENIA; NOTE; PATHOPHYSIOLOGY; PROPHYLAXIS; SICKLE CELL ANEMIA; SIDE EFFECT; STEM CELL TRANSPLANTATION; TERATOGENICITY; THROMBOCYTOSIS; TREATMENT RESPONSE;

ANEMIA, SICKLE CELL; AZACITIDINE; DNA METHYLATION; EPIGENESIS, GENETIC; GLOBINS; HEMOGLOBINS; HUMANS;

EID: 34548428815     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.1080/08880010701558188     Document Type: Note

References (13)

1. Pauling L, Itano HA. Sickle cell anemia a molecular disease. Science. 1949;110:543-548.
2. Lee A, Thomas P, Cupidore L, Serjeant B, Serjeant G. Improved survival in homozygous sickle cell disease: lessons from a cohort study. BMJ. 1995;311:1600-1602.
3. Vichinsky E, Hurst D, Earles A, Kleman K, Lubin B. Newborn screening for sickle cell disease: effect on mortality. Pediatrics. 1988;81:749-755.
4. Serjeant GR, Higgs DR, Hambleton IR. Elderly survivors with homozygous sickle cell disease. N Engl J Med. 2007;356:642-643.
5. Goldberg MA, Husson MA, Bunn HF. Participation of hemoglobins A and F in polymerization of sickle hemoglobin. J Biol Chem. 1977;252:3414-3421.
6. Nagel RL, Bookchin RM, Johnson J, et al. Structural bases of the inhibitory effects of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S. Proc Natl Acad Sci U S A. 1979;76:670-672.
7. Saunthararajah Y, Hillery CA, Lavelle D, et al. Effects of 5-aza-2′-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood. 2003;102:3865-3870.
8. Milhem M, Mahmud N, Lavelle D, et al. Modification of hematopoietic stem cell fate by 5-aza-2′-deoxycytidine and trichostatin A. Blood. 2004.
9. Koshy M, Dorn L, Bressler L, et al. 2-Deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia. Blood. 2000;96:2379-2384.
10. DeSimone J, Koshy M, Dorn L, et al. Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia. Blood. 2002;99:3905-3908.
11. Ley TJ, DeSimone J, Anagnou NP, et al. 5-Azacytidine selectively increases gamma-globin synthesis in a patient with beta+ thalassemia. N Engl J Med. 1982;307:1469-1475.
12. Ley TJ, Nienhuis AW. Induction of hemoglobin F synthesis in patients with beta thalassemia. Annu Rev Med. 1985;36:485-498.
13. Saunthararajah Y, Lavelle D, DeSimone J. DNA hypo-methylating agents and sickle cell disease. Br J Haematol. 2004;126:629-636.